Beam Therapeutics Inc.
Beam Therapeutics Inc. (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines using base editing, a gene-editing approach designed to change a single DNA base without creating a double-stranded break. Its platform combines base editors with delivery technologies, including electroporation for… From the company’s description.
Over the twelve months to Sep 30, 2026, Beam Therapeutics Inc. reported revenue of $146.64M, up 163.3% from a year earlier, and a net loss of $107.10M. Its operating margin was −267.7%, and operations used $388.65M in cash. In fiscal 2025, it reported revenue of $139.74M, up 120.0% from fiscal 2024, and a net loss of $79.99M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Beam Therapeutics Inc. does
In the company’s own words
Beam Therapeutics Inc. (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines using base editing, a gene-editing approach designed to change a single DNA base without creating a double-stranded break. Its platform combines base editors with delivery technologies, including electroporation for cells edited outside the body and lipid nanoparticles (LNPs) for in vivo delivery, alongside internal manufacturing capabilities. Its clinical-stage programs target sickle cell disease, alpha-1 antitrypsin deficiency, glycogen storage disease type 1a and phenylketonuria. Risto-cel is an investigational, patient-specific stem cell therapy for sickle cell disease; BEAM-302, BEAM-301 and BEAM-304 are liver-targeted LNP candidates for genetic diseases. The company also pursues collaborations and licenses that extend its technology to partner programs; partners include Pfizer, Apellis and Eli Lilly. Beam operates a 100,000-square-foot current good manufacturing practice facility in North Carolina, designed to support cell therapy and in vivo delivery programs and potential commercial supply.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1745999
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Beam Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Beam Therapeutics Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Beam Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Beam Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Beam Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Beam Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”